Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology
WALB,
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Therapeutic Applications of Innate Immune Modulation…
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on…
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
PR Newswire PRINCETON, N.J., Oct. 5, 2017 PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ --. (Nasdaq: ) (Soligenix or the Company), a late-stage biopharmaceutical company…
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX ) (Soligenix or the Company), a late-stage…
PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) modulate the innate immune response and have…
PRINCETON, N.J., Oct. 5, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
Information contained on this page is provided by an independent third-party content provider.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
Information contained on this page is provided by an independent third-party content provider.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
SOURCE Soligenix, Inc. 2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J.
PR Newswire PRINCETON, N.J., Sept. 20, 2017 PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ --. (Nasdaq: ) (Soligenix or the Company), a late-stage biopharmaceutical company…
2017 Non-Dilutive Funding Reaches $7.5 Million PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc.
PRINCETON, N.J. "We are appreciative of the support provided by NIDCR for the previous Phase 2 clinical study and now for the…
PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
PRINCETON, N.J., Sept. 20, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
PRINCETON, N.J., Sept. 11, 2017 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
Information contained on this page is provided by an independent third-party content provider.
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…
SOURCE Soligenix, Inc. PRINCETON, N.J. Details of the Oral Presentation: Innate Defense Regulators (IDRs) as an Agnostic…